Capricor Therapeutics announces issuance of key U.S. patent on exosome technology
Capricor Therapeutics announced that the USPTO has issued U.S. Patent 9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes. This patent, entitled "Exosomes and Micro-ribonucleic Acids for Tissue Regeneration," is expected to run until at least 2033. December 13, 2017